Synthetic mRNA comprising apoptin protein coding sequence and use thereof
The use of sequentially linked synthetic mRNA encoding apoptin protein effectively induces cancer cell death, overcoming expression and immune response issues in existing treatments, offering a promising approach for cancer therapy with improved efficacy.
Patent Information
- Application Number
- PCT/KR2024/002830
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-03-06
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods for developing cancer treatments using apoptin protein, such as viral and bacterial expression vectors, face challenges with low expression levels and immune responses, limiting their therapeutic efficacy and durability.
Development of synthetic mRNA comprising a 5'-cap, 5'-UTR, apoptin protein coding sequence, 3'-UTR, and poly A tail sequence, which is sequentially linked and shown to effectively induce cancer cell death in human and animal-derived cancer cells, including a pharmaceutical composition and health functional food formulation.
The synthetic mRNA significantly increases cancer cell death rates, with up to three times higher cell death in treated cells compared to controls, demonstrating potential for enhanced cancer treatment efficacy with reduced immune response.
Smart Images

Figure KR2024002830_21112024_PF_FP_ABST
Abstract
Description
Synthetic mRNA comprising an apoptotic protein coding sequence and uses thereof
[0001] The present invention relates to a synthetic mRNA comprising a coding sequence of an apoptotic protein and to uses thereof.
[0002] Apoptin, a 121-amino acid protein derived from the chicken infectious anemia virus, is known to have a specific apoptotic effect on cancer cells. While it does not induce apoptosis in normal cells, it exhibits specific apoptosis-inducing effects in various cancer cells, including liver cancer, lung cancer, blood cancer, and skin cancer. Therefore, various studies are being conducted to develop genomes that can produce or deliver apoptin protein for the development of anticancer treatments for humans and animals. However, due to issues such as the ineffective expression of high concentrations of apoptin protein in patients, the development of cancer treatments using apoptin has not been reported to date.
[0003] Various studies have been reported on the development of cancer therapeutics using proteins with cancer cell-killing properties, such as apoptosis. These studies primarily explore methods for expressing these proteins using viral or bacterial expression vectors. However, when expressed as a protein, the amount is insufficient for therapeutic use. Furthermore, when developed as a therapeutic and administered as a second or third dose, the formation of antibodies against the first dose can reduce therapeutic efficacy, leading to potential drawbacks.
[0004] Meanwhile, Korean Patent No. 0528755 discloses a 'gene delivery vehicle for expressing apoptosis-inducing protein VP2 and / or apoptin' using an adenovirus vector, and Korean Patent No. 0561985 discloses a 'tumor-specific apoptin expression cassette and an adenovirus expression vector comprising the same', but there is no description of the 'synthetic mRNA comprising an apoptin protein coding sequence and its use' of the present invention.
[0005] The present invention was derived from the above-mentioned needs, and the inventors of the present invention prepared a synthetic mRNA in which a 5'-cap, a 5'-UTR (untranslated region), an apoptotic protein coding sequence, a 3'-UTR, and a poly A tail sequence were sequentially linked, and treated the mRNA to Hep-2 cells, which are human-derived cancer cells, or DF-1 cells, which are animal-derived cancer cells, respectively. As a result, it was confirmed that the cell death rate when treated with the synthetic mRNA according to the present invention increased by about 2 to 3 times or more compared to the untreated control group, thereby completing the present invention.
[0006] To solve the above problem, the present invention provides a synthetic mRNA for inhibiting or killing cancer cell growth consisting of the base sequence of sequence number 1.
[0007] In addition, the present invention provides a method for producing a synthetic mRNA for inhibiting or killing cancer cell growth, comprising a step of synthesizing a 5'-cap, a 5'-untranslated region (UTR), an apoptotic protein coding sequence, a 3'-UTR, and a poly A tail sequence so as to be sequentially connected.
[0008] In addition, the present invention provides a pharmaceutical composition for preventing or treating cancer, which comprises the synthetic mRNA as an active ingredient.
[0009] In addition, the present invention provides a health functional food composition for preventing or improving cancer, which contains the synthetic mRNA as an active ingredient.
[0010] Since the synthetic mRNA according to the present invention has an excellent effect of inducing apoptosis of cancer cells, it can be usefully used in the field of developing cancer therapeutic agents.
[0011] Figure 1 shows a schematic diagram (A) and base sequence (B) of the synthetic mRNA of the present invention.
[0012] Figure 2 shows the amino acid sequence translated by the apoptotic protein coding sequence (KNU12014-F) included in the synthetic mRNA of the present invention.
[0013] Figure 3 shows the results of confirming the apoptotic effect of the synthetic mRNA of the present invention on Hep-2 cells, which are human cancer cells. A shows the cell death rate of the untreated control group, and B shows the cell death rate of the experimental group treated with the synthetic mRNA of the present invention.
[0014] Figure 4 shows the results of confirming the killing effect of DF-1 cells, which are animal-derived cancer cells, by the synthetic mRNA of the present invention. A shows the cell death rate of the untreated control group, and B shows the cell death rate of the experimental group treated with the synthetic mRNA of the present invention.
[0015] Figure 5 shows the results of confirming the cancer cell killing effect in tumor-expressing BALB / c nude mice by the synthetic mRNA of the present invention. A shows the results of comparing the change in tumor volume in the control group and the mRNA inoculation group measured over time up to 18 days after inoculation, and B shows the results of comparing the tumor weights collected by sacrifice on the 18th day after inoculation.
[0016] In order to achieve the purpose of the present invention, the present invention provides a synthetic mRNA for inhibiting or killing cancer cell growth consisting of the base sequence of sequence number 1.
[0017] The synthetic mRNA consisting of the base sequence of sequence number 1 according to the present invention may be one in which a 5'-cap, a 5'-UTR (untranslated region), an apoptotic protein coding sequence, a 3'-UTR, and a poly A tail sequence are sequentially connected, and the apoptotic protein may preferably be composed of the amino acid sequence of sequence number 2, but is not limited thereto.
[0018] In the synthetic mRNA base sequence consisting of the base sequence of sequence number 1 according to the present invention, U (uridine) is N 1 -may be replaced by, but is not limited to, methlypseudouridine (m1ψ).
[0019] The present invention also provides a method for producing a synthetic mRNA for inhibiting or killing cancer cell growth, comprising a step of synthesizing a 5'-cap, a 5'-untranslated region (UTR), an apoptotic protein coding sequence, a 3'-UTR, and a poly A tail sequence so as to be sequentially connected.
[0020] In the method for producing synthetic mRNA of the present invention, the synthesis can be performed according to methods known to those skilled in the art and is not limited to a specific method.
[0021] The present invention also provides a pharmaceutical composition for preventing or treating cancer, comprising the synthetic mRNA of the present invention as an active ingredient.
[0022] In the pharmaceutical composition of the present invention, the synthetic mRNA is characterized by having an anticancer effect through inducing apoptosis of cancer cells.
[0023] The pharmaceutical composition of the present invention may further include an appropriate carrier, excipient or diluent commonly used in the manufacture of pharmaceutical compositions, and may preferably further include a stabilizer such as liposomes, but is not limited thereto.
[0024] The pharmaceutical dosage form of the composition according to the present invention can be used alone or in combination with other pharmaceutically active compounds as well as in an appropriate combination.
[0025] The pharmaceutical composition according to the present invention can be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injection solutions, respectively, according to conventional methods. Carriers, excipients, and diluents that can be included in the pharmaceutical composition including the synthetic mRNA include various compounds or mixtures including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulated, it is prepared using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrating agents, and surfactants that are commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, and capsules, and these solid preparations are prepared by mixing the synthetic mRNA with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups, and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspending agents can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases can include withepsol, macrogol, Tween 61, cocoa butter, laurin butter, and glycerogelatin.
[0026] The preferred dosage of the pharmaceutical composition of the present invention varies depending on the patient's condition and weight, the degree of disease, the drug form, the route of administration, and the period of administration, but can be appropriately selected by a person skilled in the art.
[0027] The present invention also provides a health functional food composition for preventing or improving cancer, which comprises the synthetic mRNA of the present invention as an active ingredient.
[0028] The health functional food composition of the present invention may be in any one formulation selected from powder, granules, pills, tablets, capsules, candy, syrup, and beverage, but is not limited thereto.
[0029] When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as is or used together with other foods or food ingredients, and may be used appropriately according to a conventional method. The active ingredient may be used appropriately depending on its intended use (prevention or improvement). Generally, when manufacturing a food or beverage, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for health purposes, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range.
[0030] There are no specific restrictions on the types of the above health functional foods. Examples of foods to which the above health functional food composition can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea drinks, alcoholic beverages, and vitamin complexes, and include all health foods in the conventional sense.
[0031] In addition, the health functional food composition of the present invention can be manufactured into a food, particularly a functional food. The functional food of the present invention can include commonly added ingredients. For example, it includes proteins, carbohydrates, fats, nutrients, and seasonings. For example, when manufactured into a drink, in addition to the active ingredient, a natural carbohydrate or flavoring agent can be included as an additional ingredient. The natural carbohydrate is preferably a monosaccharide (e.g., glucose, fructose, etc.), a disaccharide (e.g., maltose, sucrose, etc.), an oligosaccharide, a polysaccharide (e.g., dextrin, cyclodextrin, etc.), or a sugar alcohol (e.g., xylitol, sorbitol, erythritol, etc.). The flavoring agent can be a natural flavoring agent (e.g., thaumatin, stevia extract, etc.) or a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
[0032] In addition to the above health functional food composition, various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. may be further contained. The ratio of these added components is not particularly important, but is generally selected within the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health functional food composition of the present invention.
[0033]
[0034] Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.
[0035]
[0036] Example 1. Preparation of synthetic mRNA
[0037] IVT (in vitro transcribed) mRNA was synthesized in which the 5'-cap, 5'-UTR (untranslated region), apoptotic protein (KNU12014-F) coding sequence, 3'-UTR, and poly A tail sequence were sequentially connected from the 5' end, and all U (uridine) in the base sequence of the mRNA were replaced with N 1 -Methlypseudouridine (m1ψ) was replaced with and synthesized (Fig. 1). The 5'-UTR was derived from human α-globulin mRNA, the 3'-UTR was derived from mitochondrial 12S ribosomal RNA, and the apoptotic protein (KNU12014-F) coding sequence was cloned from the gene encoding the VP3 protein of the chicken infectious anemia virus KNU12014 strain possessed by the present inventors. Using a synthetic DNA in which the 5'-cap, 5'-UTR (untranslated region), apoptotic protein (KNU12014-F) coding sequence, 3'-UTR, and poly A tail sequence were sequentially connected from the 5' end, mRNA was produced using an mRNA synthesis kit (HiScribe T7 mRNA Kit, NEB) as a template. The amino acids translated by the above-mentioned apoptotic protein coding sequence are composed of a 121 amino acid sequence including LRS (leucyl-tRNA synthetase), NLS 1 (nuclear localization signal 1), NES (nuclear export signal), and NLS 2 (nuclear localization signal 2) (Fig. 2).
[0038]
[0039] Example 2. Analysis of the cancer cell killing effect of synthetic mRNA.
[0040] In order to analyze the cancer cell killing effect of the synthetic mRNA according to the present invention, the killing effect on human-derived cancer cells, Hep-2 cells (ATCC, CCL-23) and animal-derived cancer cells, DF-1 cells (ATCC, CRL-12203) were measured using flow cytometry.
[0041] Specifically, 1X10 Hep-2 cells or DF-1 cells were seeded in a 6-well plate for cell culture. 6 After dividing into cells at a concentration of 100 μg and culturing for 24 hours to form a monolayer, 100 ng of the synthetic mRNA of Example 1 was treated and cultured for 6 to 7 days. After that, the treated cells were digested using 0.25% trypsin-EDTA, the cells were harvested, and the cells were stained using an apoptosis detection kit (Annexin V-FITC Apoptosis Detection Kit, AB) according to the kit manual, and then cell death was confirmed using a flow cytometer (Beckman Coulter).
[0042] As a result, when the synthetic mRNA according to the present invention was treated to Hep-2 cells, which are human-derived cancer cells, the cell death rate was 46.5%, which was confirmed to be about two times higher than that of the untreated control group (Fig. 3), and when the synthetic mRNA according to the present invention was treated to DF-1 cells, which are animal-derived cancer cells, the cell death rate was confirmed to be 76.69%, which was confirmed to be about three times higher than that of the untreated control group (Fig. 4).
[0043]
[0044] Example 3. Analysis of the cancer cell killing effect of synthetic mRNA in cancer cell-expressing animals.
[0045] In order to evaluate the cancer cell killing effect of the synthetic mRNA according to the present invention in cancer cell-expressing animals, human-derived cancer cells, Hep-2 cells (ATCC, CCL-23), were xenografted into BALB / c nude mice, and then the synthetic mRNA according to the present invention was inoculated to analyze the degree of cancer cell killing.
[0046] Specifically, 1x10 per 4-week-old BALB / c nude mice 6 Canine Hep-2 cells were inoculated to transplant cancer cells, and after 1 week, a mixture of Folate-Liposome (PEGylated, Creative Biolabs) and the synthetic mRNA of the present invention was mixed and injected intratumorally at a dose of approximately 5 μg / animal at intervals of 3 to 4 days. The tumor volume and tumor weight were measured to compare the degree of cancer cell death. The tumor volume was calculated by measuring the size of the long axis (a) and short axis (b) of the tumor using the formula (axb 2 x0.5) was calculated, and the tumor weight was compared by measuring the weight of the tumor collected from BALB / c nude mice sacrificed at the end of the test. The group inoculated with Folate-Liposome alone was used as a control group.
[0047] As a result, the tumor volume in the vaccinated group decreased compared to the control group from 7 days after inoculation, and at 18 days after inoculation, the tumor volume in the mRNA vaccinated group (299±182 mm 3 ) was the control group (996±404 mm 3 ) was significantly reduced to 30% of the control group, and the tumor weight was also significantly reduced to 22% of the control group (0.99±0.22 g) in the inoculated group (0.22±0.08 g) (Fig. 5).
Claims
1. Synthetic mRNA for suppressing cancer cell growth or killing cancer cells consisting of the base sequence of sequence number 1.
2. In the first paragraph, the synthetic mRNA is characterized in that a 5'-cap, a 5'-UTR (untranslated region), an apoptotic protein coding sequence, a 3'-UTR, and a poly A tail sequence are sequentially connected, a synthetic mRNA for inhibiting cancer cell growth or killing. A method for producing a synthetic mRNA for inhibiting or killing cancer cell growth, comprising a step of synthesizing a 3.5'-cap, a 5'-UTR (untranslated region), an apoptotic protein coding sequence, a 3'-UTR, and a poly A tail sequence so that they are sequentially connected.
4. A pharmaceutical composition for preventing or treating cancer, comprising the synthetic mRNA of claim 1 or 2 as an active ingredient.
5. A pharmaceutical composition for preventing or treating cancer, characterized in that the composition has an anticancer effect by inducing apoptosis of cancer cells in the fourth paragraph.
6. A pharmaceutical composition for preventing or treating cancer, characterized in that, in addition to the synthetic mRNA in paragraph 4, it further comprises a pharmaceutically acceptable carrier, excipient or diluent.
7. A pharmaceutical composition for preventing or treating cancer, characterized in that the composition in claim 4 is prepared in any one formulation selected from among capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols.
8. A health functional food composition for preventing or improving cancer, comprising the synthetic mRNA of paragraph 1 or 2 as an active ingredient.
9. A health functional food composition for preventing or improving cancer, characterized in that the composition is in the form of any one of powder, granules, pills, tablets, capsules, candy, syrup, and beverage in accordance with paragraph 8.
Citation Information
Patent Citations
Methods and means for inducing apoptosis by interference in RNA processing
EP0924296A2
Cancer-specific apoptin-expression cassette and adenovirus expression vector comprising the same
KR100561985B1
Synthetic mRNA comprising sequence encoding apoptin and uses thereof
KR102570209B1
KR20230043111A
